Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Neogenomics Inc (NEO)

Neogenomics Inc (NEO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Neogenomics Inc 9490 NEOGENOMICS WAY FORT MYERS FL 33912 USA

www.neogenomics.com P: 239-768-0600 F: 239-690-4237

Description:

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States.

Key Statistics

Overview:

Market Capitalization, $K 1,798,814
Enterprise Value, $K 1,456,324
Shares Outstanding, K 127,666
Annual Sales, $ 591,640 K
Annual Net Income, $ -87,970 K
Last Quarter Sales, $ 155,550 K
Last Quarter Net Income, $ -14,330 K
EBIT, $ -107,730 K
EBITDA, $ -32,270 K
60-Month Beta 1.10
% of Insider Shareholders 1.30%
% of Institutional Shareholders 98.50%
Float, K 126,006
% Float 98.70%
Short Volume Ratio 0.55

Growth:

1-Year Return -10.25%
3-Year Return -72.86%
5-Year Return -32.83%
5-Year Revenue Growth 113.79%
5-Year Earnings Growth -338.46%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.03 on 02/20/24
Latest Earnings Date 04/30/24
Earnings Per Share ttm -0.30
EPS Growth vs. Prev Qtr 66.67%
EPS Growth vs. Prev Year 80.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

NEO Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -4.13%
Return-on-Assets % -2.33%
Profit Margin % -14.87%
Debt/Equity 0.00
Price/Sales 3.04
Price/Cash Flow 49.91
Price/Book 1.91
Book Value/Share 7.39
Interest Coverage -13.05
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar